Key result
Clopidogrel nonresponders had a significantly higher rate of thromboembolic complications than responders (17.4% vs 5.6%) after pipeline embolization device placement for intracranial aneurysms.
Why the study?
Does platelet function testing and subsequent antiplatelet modification reduce thromboembolic complications in patients undergoing pipeline embolization device placement for intracranial aneurysms?
Population
402 patients with intracranial aneurysms undergoing 414 pipeline embolization device procedures
Comparison
Platelet function testing to identify… vs Clopidogrel responders, or nonresponders who…
Design
Cohort
Authors
Loading...
Clopidogrel nonresponse was associated with higher thromboembolic risk after stroke; leaves open whether testing or switching improves outcomes.
Cohort (n=402)
Yes
Does platelet function testing and subsequent antiplatelet modification reduce thromboembolic complications in patients undergoing pipeline embolization device placement for intracranial aneurysms?
Absolute Event Rate: 17.4% vs 5.6%
Platelet function testing before pipeline embolization device placement identifies clopidogrel nonresponders who benefit from switching to ticagrelor or receiving a clopidogrel boost to reduce thromboembolic complications.
Adeeb et al. (2017) conducted a cohort in intracranial aneurysms (n=402). Clopidogrel nonresponse vs. Clopidogrel response was evaluated on thromboembolic complications. Clopidogrel nonresponders had a significantly higher rate of thromboembolic complications than responders (17.4% vs 5.6%) after pipeline embolization device placement for intracranial aneurysms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: